ArticleFocus (American Psychiatric Publishing)2021
Contrasting Typical and Atypical Antipsychotic Drugs.
Article in Focus (American Psychiatric Publishing), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Effect of 5-HT1A Receptor Partial Agonists of the Azapirone Class as an Add-On Therapy on Psychopathology and Cognition in Schizophrenia: A Systematic Review and Meta-Analysis.The international journal of neuropsychopharmacology · 2023Pooled it
- Cariprazine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder: A case report.Biomedical reports · 2026Article
- "Chill packs" self-administered olanzapine as psychiatric harm reduction for methamphetamine-induced psychosis: a narrative review of the existing evidence base.Harm reduction journal · 2026Review
- Article
- Uncovering novel therapeutics for schizophrenia: a multitarget approach using the CANDO platform.bioRxiv : the preprint server for biology · 2026Article
- Decoding GPCR signaling in living cells to advance early therapeutic discovery for neurological disorders.Frontiers in molecular neuroscience · 2026Review
- Rational antipsychotic polypharmacy in psychotic and bipolar disorders: A focus on D2 receptor partial agonists.The mental health clinician · 2025Article
- The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia.Journal of psychopharmacology (Oxford, England) · 2025Article
- Exploring Medication Errors with Antipsychotics in Saudi Arabia: Insights from a Nationwide Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Preliminary Data Regarding the Alleviating Effects of Haloperidol and Risperidone on the Short-Term Memory and Associative Learning in a Zebrafish Model of Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Comparing the Metabolic, Systemic, and Neuropsychiatric Impacts of Olanzapine and Clozapine in Patients with Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Diagnostic Patterns and Racial/Ethnic Differences in Antipsychotic Prescribing Among Privately Insured Youth.Translational issues in psychological science · 2025Article
- MRI-based insights into brain structural and functional alterations in schizophrenia treated with risperidone.Frontiers in psychiatry · 2025Review
- Evaluation of Antipsychotic-Induced Neuroleptic Malignant Syndrome Using a Self-Organizing Map.Cureus · 2024Article
- Interictal psychosis of epilepsy: What is the role of the neurologist?Epilepsy & behavior reports · 2024Article
- Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2024Article
- Investigating the effects of antipsychotic drugs as a treatment for improving the activity of themicroPublication biology · 2024Article
- Augmentation therapy with serotoninSchizophrenia research. Cognition · 2023Article
- Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system.Heliyon · 2023Article
- Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy.Cureus · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The beliefs that antipsychotic drugs (APDs) are 1) effective
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.